522 related articles for article (PubMed ID: 19038308)
61. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
[TBL] [Abstract][Full Text] [Related]
62. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
Poirier D
Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
[TBL] [Abstract][Full Text] [Related]
63. Estradiol as an anti-aromatase agent in human breast cancer cells.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):12-7. PubMed ID: 16413774
[TBL] [Abstract][Full Text] [Related]
64. 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
Aka JA; Mazumdar M; Chen CQ; Poirier D; Lin SX
Mol Endocrinol; 2010 Apr; 24(4):832-45. PubMed ID: 20172961
[TBL] [Abstract][Full Text] [Related]
65. Mutual regulations and breast cancer cell control by steroidogenic enzymes: Dual sex-hormone receptor modulation upon 17β-HSD7 inhibition.
Sang X; Han H; Li T; Lin SX
J Steroid Biochem Mol Biol; 2019 Oct; 193():105411. PubMed ID: 31207361
[TBL] [Abstract][Full Text] [Related]
66. The selective estrogen enzyme modulator (SEEM) in breast cancer.
Chetrite GS; Pasqualini JR
J Steroid Biochem Mol Biol; 2001; 76(1-5):95-104. PubMed ID: 11384867
[TBL] [Abstract][Full Text] [Related]
67. Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells.
Walter G; Liebl R; von Angerer E
Arch Pharm (Weinheim); 2004 Dec; 337(12):634-44. PubMed ID: 15597397
[TBL] [Abstract][Full Text] [Related]
68. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
69. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
70. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
71. Expression of COX-2 and steroid converting enzymes in breast cancer.
Gunnarsson C; Jansson A; Holmlund B; Ferraud L; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
Oncol Rep; 2006 Aug; 16(2):219-24. PubMed ID: 16820896
[TBL] [Abstract][Full Text] [Related]
72. 17Beta-hydroxysteroid dehydrogenases in human bone cells.
Dong Y; Qiu QQ; Debear J; Lathrop WF; Bertolini DR; Tamburini PP
J Bone Miner Res; 1998 Oct; 13(10):1539-46. PubMed ID: 9783542
[TBL] [Abstract][Full Text] [Related]
73. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders.
Ito K; Utsunomiya H; Suzuki T; Saitou S; Akahira J; Okamura K; Yaegashi N; Sasano H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):136-40. PubMed ID: 16406263
[TBL] [Abstract][Full Text] [Related]
74. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
75. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
76. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
77. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
[TBL] [Abstract][Full Text] [Related]
78. 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis.
Nagasaki S; Suzuki T; Miki Y; Akahira J; Kitada K; Ishida T; Handa H; Ohuchi N; Sasano H
Cancer Res; 2009 Feb; 69(4):1392-9. PubMed ID: 19190350
[TBL] [Abstract][Full Text] [Related]
79. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
[TBL] [Abstract][Full Text] [Related]
80. Differential effects of progestins on breast tissue enzymes.
Pasqualini JR
Maturitas; 2003 Dec; 46 Suppl 1():S45-54. PubMed ID: 14670645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
